Federal Officials Accuse uniQure of Deception Over Huntington’s Drug Approval

Federal health officials from the FDA and HHS have publicly accused the biotech firm uniQure of providing misleading information regarding the approval process for its Huntington’s disease treatment. This rare public rebuke from federal agencies is highly unusual, especially for medical products that are still under regulatory consideration. The accusations come at a time when the FDA is facing significant pressure from U.S. lawmakers following the recent rejection of several rare-disease medications. Industry analysts suggest that such a direct confrontation by regulators severely undermines uniQure’s credibility and casts doubt on the future of its clinical pipeline. Consequently, the news is expected to have a significant negative impact on the company's stock price and investor confidence in the broader biotech sector. The situation highlights the growing tension between regulatory bodies and pharmaceutical companies over the transparency of the drug approval process.